The review article about sudden infant death syndrome (SIDS), by Carl Hunt and Fern Hauck,1 was enlightening. However, it was somewhat discouraging in its equivocal negation of the utility of postdelivery electrocardiography. It is the contention of this observer that for any baby with a family history of sudden cardiac death, with evidence of conduction defects or ventricular arrhythmia on cardiorespiratory monitoring, or exhibiting apnea neonatorum, investigations must include electrocardiography to test for cardiac channelopathy such as short QT syndrome, long QT syndrome, Brugada syndrome or progressive cardiac conduction defect, any of which would exclude the diagnosis of SIDS.

John Morphet
Cardiologist
Niagara-on-the-Lake, Ont.

REFERENCE
DOI:10.1503/cmaj.1060141

[The authors respond:] We appreciate John Morphet’s letter and are pleased to respond. In our article, we stated that electrocardiography is not recommended as a routine strategy for assessing future risk of sudden infant death syndrome.1 The cost-effectiveness of such screening in infants without a family history of sudden cardiac death has been studied, but the results have been mixed. The authors of the only North American study concluded that electrocardiography was indicated only in selected groups of infants, such as those with symptoms related to apnea or bradycardia or with a family history of sudden infant death syndrome or long QT syndrome.2

Both short QT syndrome and long QT syndrome have been reported to cause sudden unexpected death in infancy.2,3 Our review did not address the indications for electrocardiography in infants with a family history of sudden cardiac death, but we agree that any baby with a family history of sudden unexpected death in infancy, sudden cardiac death, conduction defect or ventricular arrhythmia should undergo electrocardiography.

It was also outside the scope of our review to discuss recommendations for the clinical evaluation of infants who have experienced an apparent life-threatening event. In a recent review of the yield of diagnostic testing in 243 such infants, electrocardiography was considered to be indicated in only 25%
of the cases and all of the electrocardiograms were normal. There have been 2 reported cases of infants who experienced an apparent life-threatening event attributed to long QT syndrome, and there is 1 reported case of an infant with Brugada syndrome who experienced an apparent life-threatening event associated with ventricular fibrillation, but his QT interval was normal. Hence, considering the rarity of apparent life-threatening events caused by long QT syndrome or short QT syndrome, there has not been any formal recommendation that all infants experiencing an apparent life-threatening event should have electrocardiography as part of the clinical evaluation following the event, except insofar as indicated by the baby’s specific history and initial clinical evaluation. Although again this is outside the scope of our review, we would agree with this general approach.

Carl E. Hunt
Department of Pediatrics
Uniformed Services University of the Health Sciences
Bethesda, Md.
Fern R. Hauck
Departments of Family Medicine and Public Health Sciences
University of Virginia
Charlottesville, Va.

REFERENCES

Clarification of the CMA’s position concerning induced abortion

A recent editorial in CMAJ and subsequent letters to the editor have raised several questions about the Canadian Medical Association’s position on induced abortion. I would like to clarify that position with this illustrative case.

Case: You are a family physician practising at a community health care centre. A 25-year-old patient recently had a positive pregnancy test and estimates that she is 7 weeks’ pregnant. She asks if you will perform a therapeutic abortion. If not, will you refer her right away to someone who will perform it? You are morally opposed to abortion. What are your obligations to this patient?

Discussion: CMA policy states that “a physician should not be compelled to participate in the termination of a pregnancy.” In addition, “a physician whose moral or religious beliefs prevent him or her from recommending or performing an abortion should inform the patient of this so that she may consult another physician.”

You should therefore advise the patient that you do not provide abortion services. You should also indicate that because of your moral beliefs, you will not initiate a referral to another physician who is willing to provide this service (unless there is an emergency).

However, you should not interfere in any way with this patient’s right to obtain the abortion. At the patient’s request, you should also indicate alternative sources where she might obtain a referral. This is in keeping with the obligation spelled out in the CMA policy: “There should be no delay in the provision of abortion services.”

Jeff Blackmer
Executive Director, Office of Ethics
Canadian Medical Association
Ottawa, Ont.

REFERENCES

Editor’s note: We received a large number of letters in response to the editorial by Rodgers and Downie, with particular regard to the CMA’s policy on induced abortion. We asked the CMA to assist our readers by clarifying their position using a case-based example, which they have provided here. We will not publish any further letters on this topic, unless they present new information or state a new position on this matter.

Corrections

In the supplement to the March 13 issue of CMAJ, the term “neuropathy” was omitted from a list that appears on page 15 under the heading “Diabetes-related vasculopathy” and the subheading “Microvasculature.” That list should have read as follows: retinopathy, nephropathy, neuropathy.

REFERENCE

DOI:10.1503/cmaj.070432

A recent News article contained an error concerning the vaccine that GlaxoSmithKline is developing. The sentence “GlaxoSmithKline’s Cervarix will block HPV strains linked to 80% of cervical cancers” should have read as follows: “GlaxoSmithKline’s Cervarix may block HPV strains linked to 80% of cervical cancers.” We apologize for any inconvenience this error may have caused.

REFERENCE
1. Comeau P. Debate begins over public funding for HPV vaccine. CMAJ 2007;176(7):915-4

DOI:10.1503/cmaj.070433